Related Experiment Videos
Infrequent RAS oncogene mutations in human prostate cancer
J W Moul1, P A Friedrichs, R S Lance
1Department of Surgery Uniformed Services, University of the Health Sciences, Bethesda, MD 20814-4799.
The Prostate
|January 1, 1992
Summary
RAS gene mutations are infrequent in prostate cancer. This study found no definite point mutations in H-RAS, K-RAS, or N-RAS genes in American males with prostate carcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The RAS gene family (H-RAS, K-RAS, N-RAS) is crucial in human tumors, with mutations often found at specific codons.
- Conflicting data exists on RAS mutation incidence in prostate cancer, with some studies reporting low rates and others higher rates in specific populations.
Purpose of the Study:
- To investigate the incidence of RAS gene mutations (H-RAS, K-RAS, N-RAS) at codons 12, 13, and 61 in radical prostatectomy specimens from American males.
Main Methods:
- DNA extraction from 24 archival, formalin-fixed, paraffin-embedded prostatectomy specimens.
- Polymerase chain reaction (PCR) amplification of RAS gene codons.
- Mutation detection using mutation-specific oligonucleotide probe hybridization on southern and slot blots, with rigorous validation.
Main Results:
- No definite point mutations in H-RAS, K-RAS, or N-RAS genes were detected in the analyzed prostate cancer specimens.
- Results were confirmed through multiple independent PCRs and hybridizations by three investigators, using positive and negative controls.
Conclusions:
- RAS gene mutations appear to be infrequent in clinical prostate carcinomas in American males.
- The findings contribute to resolving conflicting data regarding RAS mutation prevalence in prostate cancer.